These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7655155)

  • 61. Toward microRNA-based therapeutics for heart disease: the sense in antisense.
    van Rooij E; Marshall WS; Olson EN
    Circ Res; 2008 Oct; 103(9):919-28. PubMed ID: 18948630
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Silencing of human c-myc oncogene expression by poly-DNP-RNA.
    Shen L; Zhang C; Ambrus JL; Wang JH
    Oligonucleotides; 2005; 15(1):23-35. PubMed ID: 15788898
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Functional correction and cognitive improvement in dystrophic mice using splice-switching tricyclo-DNA oligomers].
    Goyenvalle A; Griffith G; Avril A; Amthor H; Garcia L
    Med Sci (Paris); 2015 Mar; 31(3):253-6. PubMed ID: 25855277
    [No Abstract]   [Full Text] [Related]  

  • 64. Inhibition of VEGF mRNA by 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions.
    Morita K; Yamate K; Kurakata S; Abe K; Watanabe K; Koizumi M; Imanishi T
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(4-6):503-21. PubMed ID: 16838842
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Splicing-correcting therapeutic approaches for retinal dystrophies: where endogenous gene regulation and specificity matter.
    Bacchi N; Casarosa S; Denti MA
    Invest Ophthalmol Vis Sci; 2014 May; 55(5):3285-94. PubMed ID: 24867912
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antisense therapy specific to mutated K-ras gene in hamster pancreatic cancer model. Can it inhibit the growth of 5-FU and MMC-resistant metastatic and remetastatic cell lines?
    Morioka CY; Saito S; Machado MC; Ohzawa K; Kubrusly MS; Cunha JE; Watanabe A
    In Vivo; 2004; 18(2):113-7. PubMed ID: 15113037
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hybridization of antisense reagents to RNA.
    Sohail M; Southern EM
    Curr Opin Mol Ther; 2000 Jun; 2(3):264-71. PubMed ID: 11249620
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.
    Aartsma-Rus A; Krieg AM
    Nucleic Acid Ther; 2019 Jun; 29(3):115. PubMed ID: 30964415
    [No Abstract]   [Full Text] [Related]  

  • 70. Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody.
    Meissner JM; Toporkiewicz M; Czogalla A; Matusewicz L; Kuliczkowski K; Sikorski AF
    J Control Release; 2015 Dec; 220(Pt A):515-528. PubMed ID: 26585505
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Potential for transcatheter application of antisense oligonucleotides for the treatment of vascular diseases.
    Morishita R; Gibbons GH; Dzau VJ
    J Interv Cardiol; 1995 Aug; 8(4):377-81. PubMed ID: 10155251
    [No Abstract]   [Full Text] [Related]  

  • 72. [Perspectives of clinical oncology for the '90's].
    Obrecht JP
    Onkologie; 1990 Oct; 13(5):333-6. PubMed ID: 2082227
    [No Abstract]   [Full Text] [Related]  

  • 73. [Molecular therapy for vascular disease using an oligonucleotide-based strategy].
    Miyake T; Morishita R
    Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):158-62. PubMed ID: 17379964
    [No Abstract]   [Full Text] [Related]  

  • 74. Exploiting the p53 Pathway for Therapy.
    Cheok CF; Lane DP
    Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 28193768
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Presentations from the 2nd NIH Symposium on Therapeutic Oligonucleotides: Targeting Transcription Factors and Signaling Pathways. Bethesda, Maryland, USA. December 5, 1997.
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):113-84. PubMed ID: 9669868
    [No Abstract]   [Full Text] [Related]  

  • 76. Gene-modified cells for the treatment of cancer.
    Whartenby KA; Abraham GN; Calabresi PA; Abboud CN; Calabresi P; Marrogi A; Freeman SM
    Pharmacol Ther; 1995 Apr; 66(1):175-90. PubMed ID: 7630929
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunologic consequences of nucleic acid therapy.
    Pisetsky DS
    Antisense Res Dev; 1995; 5(3):219-25. PubMed ID: 8785478
    [No Abstract]   [Full Text] [Related]  

  • 78. Anti-sense and gene therapy approaches to the treatment of lymphomas.
    Devereux S; Cotter FE
    Baillieres Clin Haematol; 1996 Dec; 9(4):819-34. PubMed ID: 9138619
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antisense therapy: therapeutic magic bullet or theoretical dream?
    Turner C
    Clin Oncol (R Coll Radiol); 1997; 9(1):54-8. PubMed ID: 9039815
    [No Abstract]   [Full Text] [Related]  

  • 80. VP22 flips the switch on cell death.
    Weitzman MD
    Mol Ther; 2003 Feb; 7(2):146-7. PubMed ID: 12638542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.